Emerging Role of Microtubule-Associated Protein 2 as a Prognostic Factor for Renal Dysfunction

Fatima Ghazi Talab; Hind Shakir Ahmed

doi:10.30526/38.3.4030

Authors

Fatima Ghazi Talab College of Medicine, Al Nahrain University, Baghdad, Iraq and Department of Chemistry/ College of Education for Pure Science (Ibn Al-Haitham)/ University of Baghdad, Baghdad, Iraq. https://orcid.org/0009-0008-9637-1418
Prof. Dr. Hind Shakir Ahmed Department of Chemistry/ College of Education for Pure Science (Ibn Al-Haitham)/ University of Baghdad, Baghdad, Iraq. https://orcid.org/0000-0001-6846-1549

DOI:

https://doi.org/10.30526/38.3.4030

Keywords:

Chronic kidney disease, Glomerular filtration rate, Lipid profilr, Microtubule associated protein 2, Renal function test

Abstract

Chronic kidney disease (CKD) is a severe medical disorder manifested by a decline in kidney function over an extended period. This leads to the accumulation of toxins and the gradual inability to remove excess waste and fluids from the body. Microtubule-associated protein 2 (MAP2) is part of a protein family that regulates microtubule structure and cellular metabolism. This study aims to analyze the effectiveness of these parameters in evaluating CKD and its associated mechanisms in Iraqi patients. The study was conducted from December 2023 to May 2024. Ninety subjects enrolled in this study: 60 patients with CKD who attended the Baghdad Teaching Hospital/Medical City/ Dialysis Unit in Baghdad, Iraq. Additionally, 30 healthy subjects were designated as the control group. Their ages ranged from 48 to 65 years. The present results indicated significantly higher serum MAP2 levels in CKD patients undergoing dialysis as compared to the control (616.10±12.25 vs. 125.48±10.14) ρg/mL. In addition, the present results revealed a significant positive correlation between serum MAP2 and levels of various parameters, including fasting glucose, lipid profile, and renal function tests. A significant negative correlation exists between serum MAP2 levels and serum total protein, albumin, and estimated glomerular filtration rate. It was found that higher levels of serum MAP2 in hemodialysis patients reveal their critical role in renal dysfunction. Therefore, this factor may serve as a biomarker of kidney injury progression among patients with CKD.

Author Biographies

Fatima Ghazi Talab, College of Medicine, Al Nahrain University, Baghdad, Iraq and Department of Chemistry/ College of Education for Pure Science (Ibn Al-Haitham)/ University of Baghdad, Baghdad, Iraq.

Department of Chemistry
Prof. Dr. Hind Shakir Ahmed, Department of Chemistry/ College of Education for Pure Science (Ibn Al-Haitham)/ University of Baghdad, Baghdad, Iraq.

Department of Chemistry/ Biochemistry

References

1. Ammirati AL. Chronic kidney disease. Rev Assoc Med Bras. 2020; 66(1):s03–s09.

https://doi.org/10.1590/1806-9282.66.S1.3.

2. Ahmed HS, Abd‑Ali E, Abdullah MR. Biochemical study on diabetic nephropathy patients. IHJPAS. 2010; 23(3):1–11. https://jih.uobaghdad.edu.iq/index.php/j/article/view/899/768.

3. Mohammed MS, Ahmed HS. Plasminogen activator urokinase receptor as a diagnostic and prognostic biomarker in type 2 diabetic patients with cardiovascular disease. J Cardiovasc Thorac Res. 2023; 15(3): 154–160. https://doi.org/10.34172%2Fjcvtr.2023.32895.

4. Verdier V, Soulage CO, Koppe L. New clinical evidence for urea toxicity. Nephrol Dial Transpl. 2022; 37(1):1–4. https://doi.org/10.1093/ndt/gfab269.

5. Ahmed HS. Serum adropin and apelin as potential markers predicting acute heart failure‑associated renal dysfunction among elderly Iraqi patients. Ann Trop Med Public Health. 2020; 23(S10):1–15. http://dx.doi.org/10.36295/ASRO.2020.231024.

6. Obert LA, Elmore SA, Ennulat D, Frazier KS. A review of specific biomarkers of chronic renal injury and their potential application in nonclinical safety assessment studies. Toxicol Pathol. 2021; 49(5):996–1023. https://doi.org/10.1177/0192623320985045.

7. Kumahor EK. The biochemical basis of renal diseases. In: Current trends in the diagnosis and management of metabolic disorders. CRC Press; 2024. p. 185–200. http://dx.doi.org/10.1201/9781003384823-11.

8. Rodriguez‑Ballestas E, Reid‑Adam J. Nephrotic syndrome. Curr Pediatr Rev. 2022; 43(2):87–99. https://doi.org/10.1542/pir.2020-001230.

9. Ahmed HS. Obesity and breast cancer: Circulating adipokines and their potential diagnostic as risk biomarkers. Int J Res Pharm Sci. 2020; 11(3):3061–3068. https://ijrps.com/index.php/home/article/view/599.

10. Stetler‑Stevenson WG. The continuing saga of tissue inhibitor of metalloproteinase 2: emerging roles in tissue homeostasis and cancer progression. Am J Pathol. 2023; 193(5):579–590.

https://doi.org/10.1016/j.ajpath.2023.01.007.

11. Yan Z, Wang G, Shi X. Advances in the progression and prognosis biomarkers of chronic kidney disease. Front Pharmacol. 2021;12:785375. https://doi.org/10.3389/fphar.2021.785375.

12. Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Anders HJ. Chronic kidney disease. Nat Rev Dis Primers. 2017; 3(1):1–24. https://doi.org/ 10.1038/nrdp.2017.88.

13. Perazella MA, Nast CC. Chronic tubulointerstitial disease. In: National Kidney Foundation Primer on Kidney Diseases, E-Book. Philadelphia (PA): Elsevier; 2022; p. 406.

14. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1–266. PMID: 11904577.

15. Kalantar‑Zadeh K, Li PK, Kovesdy CP, Liyanage T, Levin A, Tonelli M. Chronic kidney disease and the global public health challenge: the 2021 KDIGO guidelines and future outlook. Lancet. 2021; 398(10311):786–802.

16. Francis A, Harhay MN, Ong A, Tummalapalli SL, Ortiz A, Fogo AB, Jha V. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024:1–13. https://doi.org/10.1038/s41581-024-00820-6.

17. IBM. Statistical Package for the Social Sciences (SPSS)–IBM v29. Chicago (IL): IBM Corp; 2022.

18. Lin R, McDonald G, Jolly T, Batten A, Chacko B. A systematic review of prophylactic anticoagulation in nephrotic syndrome. Kidney Int Rep. 2020; 5(4):435–447. https://doi.org/10.1016/j.ekir.2019.12.001.

19. Noronha IL, Santa-Catharina GP, Andrade L, Coelho VA, Jacob-Filho W, Elias RM. Glomerular filtration in the aging population. Front Med. 2022; 9:769329. https://doi.org/10.3389/fmed.2022.769329.

20. Mohanty SK, Veerabhadrappa B, Majhi A, Suchiang K, Dyavaiah M. Age-related disease: kidneys. In: Academic Press, 2024; p. 91–117. http://dx.doi.org/10.1016/B978-0-443-15500-0.00003-7.

21. Kalantar‑Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021; 398(10302):786–802. https://doi.org/10.1016/S0140-6736(21)00519-5.

22. Wang K, Liu Q, Tang M, Qi G, Qiu C, Huang Y, Fang X. Chronic kidney disease‑induced muscle atrophy: molecular mechanisms and promising therapies. Biochem Pharmacol. 2023; 208:115407.

http://dx.doi.org/10.1016/B978-0-443-15500-0.00003-7.

23. Mohammed MS, Ahmed HS. Urokinase‑type plasminogen activator receptor as a predictive marker for cardiac disease among type 2 diabetic patients. Med J Babylon. 2023; 20(4):750–756.

https://doi.org/10.4103/MJBL.MJBL_832_23.

24. Raoof EMM, Ahmed HS. Circulating adipsin as biomarker and its implication in type 2 diabetes mellitus. Int J Drug Deliv Technol. 2022; 12(2):588–593. https://doi.org/10.25258/ijddt.12.2.21.

25. Mohammed MS, Ahmed HS. Atherogenic indices in type 2 diabetic Iraqi patients and its association with cardiovascular disease risk. J Fac Med Baghdad. 2023; 65(3):179–186.

https://doi.org/10.32007/jfacmedbagdad.2075.

26. Lee YJ, Cho S, Kim SR. Effect of alcohol consumption on kidney function: Population‑based cohort study. Sci Rep. 2021; 11(1):2381. https://doi.org/10.1038/s41598-021-81777-5.

27. Ravid JD, Chitalia VC. Molecular mechanisms underlying the cardiovascular toxicity of specific uremic solutes. Cells. 2020; 9(9):2024. https://doi.org/10.3390/cells9092024.

28. Ravid JD, Kamel MH, Chitalia VC. Uraemic solutes as therapeutic targets in CKD‑associated cardiovascular disease. Nat Rev Nephrol. 2021; 17(6):402–416.

https://doi.org/10.1038/s41581-021-00408-4.

29. Adeyomoye OI, Akintayo CO, Omotuyi KP, Adewumi AN. The biological roles of urea: a review of preclinical studies. Indian J Nephrol. 2022; 32(6):539–545. https://doi.org/10.4103%2Fijn.ijn_88_21.

30. Tahir NT, Ahmed HS, Mohsen FY. Vitamin D and risk of osteoarthritis among Iraqi patients with and without metabolic syndrome. Plant Arch. 2020; 20:2731–2736.

31. Lew SQ, Radhakrishnan J. Chronic kidney disease and gastrointestinal disorders. In: Chronic renal disease. 2020:521–539. https://doi.org/10.1016/B978-0-12-411602-3.00025-1.

32. Laville SM, Couturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, Massy ZA. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dial Transpl. 2023; 38(1):184–192. https://doi.org/10.1093/ndt/gfac045.

33. Yanai H, Adachi H, Hakoshima M, Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int J Mol Sci. 2021; 22(17):9221.

https://doi.org/10.3390/ijms22179221.

34. Zsom L, Zsom M, Salim SA, Fulop T. Estimated glomerular filtration rate in chronic kidney disease: a critical review of estimate‑based predictions of individual outcomes in kidney disease. Toxins. 2022; 14(2):127. https://doi.org/10.3390/toxins14020127.

35. Ahmed HSh, Abbas AK. The relationship between reproductive hormones and metabolic parameters in women with polycystic ovary syndrome. J Fac Med Baghdad. 2014; 56(2):234–238.

https://doi.org/10.32007/jfacmedbagdad.562483.

36. Kahraman ZB, Dizdar OS, Guna AI. The effect of hypervolemia control on proteinuria in kidney disease: a prospective interventional study. J Clin Pract Res. 2024; 46(3):234–241.

https://doi.org/ 10.14744/cpr.2024.92387.

37. Ahmed HS, Ahmed HS, Ad’hiah AH. Interleukin‑1 single nucleotide polymorphisms and risk of systemic lupus erythematosus among Iraqi patients. Meta Gene. 2020; 23:100640.

http://dx.doi.org/10.1016/j.mgene.2019.100640.

38. Vallés‑Saiz L, Peinado‑Cahuchola R, Ávila J, Hernández F. Microtubule‑associated protein Tau in murine kidney: role in podocyte architecture. Cell Mol Life Sci. 2022; 79(2):97.

https://doi.org/10.1007/s00018-021-04106-z.

39. Li L, Feng Y, Zhang J, Zhang Q, Ren J, Sun C, Li Sh, Lei X, Luo G, Hu J, Huang Y. Microtubule associated protein 4 phosphorylation‑induced epithelial‑to‑mesenchymal transition of podocyte leads to proteinuria in diabetic nephropathy. Cell Commun Signal. 2022; 20(1):115.

https://doi.org/10.1186/s12964-022-00883-7.

40. Daehn I, Casalena G, Zhang T, Shi S, Fenninger F, Barasch N, Yu L, D’Agati V, Schlondorff D, Kriz W, Haraldsson B, Bottinger EP. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J Clin Invest. 2014; 124(4):1608–1621.

https://doi.org/10.1172/jci71195.

41. Hanna RM, Ghobry L, Wassef O, Rhee CM, Kalantar‑Zadeh K. A practical approach to nutrition, protein‑energy wasting, sarcopenia, and cachexia in patients with chronic kidney disease. Blood Purif. 2020; 49(1–2):202–211. https://doi.org/10.1159/000504240.

42. Drawz P, Hostetter TH, Rosenberg ME. Slowing progression of chronic kidney disease. In: Chronic Renal Disease. Academic Press; 2020; p. 937–959. https://doi.org/10.1016/B978-0-12-815876-0.00057-7

43. Dai C, Stolz DB, Bastacky SI, St‑Arnaud R, Wu C, Dedhar S, Liu Y. Essential role of integrin‑linked kinase in podocyte biology: bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol. 2006; 17(8):2164–2175. https://doi.org/10.1681/asn.2006010033.

44. Kumar PA, Welsh GI, Raghu G, Menon RK, Saleem MA, Reddy GB. Carboxymethyl lysine induces EMT in podocytes through transcription factor ZEB2: implications for podocyte depletion and proteinuria in diabetes mellitus. Arch Biochem Biophys. 2016; 590:10–19. https://doi.org/10.1016/j.abb.2015.11.003.

45. Ahmed HSh. Correlations between serum interleukins‑2,‑4 levels and some biochemical parameters in Iraqi patients with osteoporosis. J Fac Med Baghdad. 2017; 59(3):275–279.

https://doi.org/10.32007/jfacmedbagdad.593103.

46. Li N, Jiang P, Du W, Wu Z, Li C, Qiao M, Yang X, Wu M. Siva1 suppresses epithelial‑mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci USA. 2011; 108(31):12851–12856. https://doi.org/10.1073/pnas.1017372108.

47. Luyckx VA, Rule AD, Tuttle KR, Delanaye P, Liapis H, Gandjour A, Romagnani P, Anders H‑J. Nephron overload as a therapeutic target to maximize kidney lifespan. Nat Rev Nephrol. 2022; 18(3): 171–183. https://doi.org/10.1038/s41581-021-00510-7.

48. Tahir NT, Ahmed HS, Gaiz AA. Leptin and insulin resistance in obese children. Al‑Kindy Col Med J. 2014; 10(2):36–40. https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/449.

49. Tahir NT, Ahmed HS, Ahmed HS. Studies on the role of retinol binding protein‑4 in type 2 diabetic Iraqi patients with metabolic syndrome. Nucleus. 2023:1–7.

https://doi.org/10.32007/jfacmedbagdad.593103.

50. Li X, Zhang Y, Xing X, Li M, Liu Y, Xu A, Zhang JL. Podocyte injury of diabetic nephropathy: novel mechanism discovery and therapeutic prospects. Biomed Pharmacother. 2023; 168:115670.

https://doi.org/10.1016/j.biopha.2023.115670.